Skip to main content
Premium Trial:

Request an Annual Quote

Sangamo and Millennium Sign Research Agreement

Premium

POINT RICHMOND, Calif.--Sangamo BioSciences, a privately held biotechnology company here, announced that it has signed a collaborative research agreement with Millennium Pharmaceuticals in which Millennium will pay the company to evaluate Sangamo's Universal GeneTools product in the validation of gene targets for drug discovery.

Sangamo's technology platform enables the rational design and rapid generation of highly specific zinc finger DNA recognition proteins that can selectively recognize and regulate any target gene or DNA sequence. Engineered zinc finger proteins are used to accelerate the functional analysis of newly discovered genes and to validate clinically relevant gene targets.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.